Summary
30.07 0.67(2.26%)06/21/2024
Corcept Therapeutics Inc (CORT)
Corcept Therapeutics Inc (CORT)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 2.42 | 3.78 | 4.37 | 21.50 | -5.04 | 33.86 | 187.15 | 145.83 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 30.07 | |
| Open | 29.18 | |
| High | 30.32 | |
| Low | 29.18 | |
| Volume | 933,875 | |
| Change | 0.71 | |
| Change % | 2.42 | |
| Avg Volume (20 Days) | 1,108,789 | |
| Volume/Avg Volume (20 Days) Ratio | 0.84 | |
| 52 Week Range | 20.84 - 35.00 | |
| Price vs 52 Week High | -14.10% | |
| Price vs 52 Week Low | 44.27% | |
| Range | 3.03 | |
| Gap Up/Down | -0.28 | |
Fundamentals | ||
| Market Capitalization (Mln) | 3,414 | |
| EBIDTA | 122,800,000 | |
| PE Ratio | 25.7524 | |
| PEG Ratio | 0.6100 | |
| WallStreet Target Price | 43.60 | |
| Book Value | 5.2670 | |
| Earnings Per Share | 1.0500 | |
| EPS Estimate Current Quarter | 0.2200 | |
| EPS Estimate Next Quarter | 0.2300 | |
| EPS Estimate Current Year | 0.9600 | |
| EPS Estimate Next Year | 1.2900 | |
| Diluted EPS (TTM) | 1.0500 | |
| Revenues | ||
| Profit Marging | 0.2254 | |
| Operating Marging (TTM) | 0.2009 | |
| Return on asset (TTM) | 0.1197 | |
| Return on equity (TTM) | 0.2191 | |
| Revenue TTM | 523,528,992 | |
| Revenue per share TTM | 5.1180 | |
| Quarterly Revenue Growth (YOY) | 0.3900 | |
| Quarterly Earnings Growth (YOY) | 0.7860 | |
| Gross Profit (TTM) | 396,473,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 25.7524 | |
| Forward PE | 71.4286 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 4.8158 | |
| Revenue Enterprise Value | 4.2956 | |
| EBITDA Enterprise Value | 18.8985 | |
| Shares | ||
| Shares Outstanding | 104,112,000 | |
| Shares Float | 85,361,501 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.27 | |
| Insider (%) | 11.38 | |
| Institutions (%) | 86.11 | |
06/14 10:50 EST - zacks.com
Corcept Therapeutics (CORT) is a Top-Ranked Momentum Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Corcept Therapeutics (CORT) is a Top-Ranked Momentum Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
06/07 14:34 EST - investors.com
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
The top five biotech stocks today have several commonalities. Among them are strong ratings.
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
The top five biotech stocks today have several commonalities. Among them are strong ratings.
06/07 14:34 EST - investors.com
Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5
The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.
Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5
The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.
06/03 08:00 EST - globenewswire.com
Corcept Therapeutics Announces Presentations of Results of Pivotal Phase 3 GRACE Trial Evaluating Relacorilant in Patients with Hypercortisolism (Cushing's Syndrome)
MENLO PARK, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the results from GRACE, the Phase 3 trial of its proprietary selective cortisol modulator relacorilant in patients with hypercortisolism (Cushing's syndrome), will be presented at the Endocrine Society (ENDO) annual meeting in Boston (June 3) and the Heart in Diabetes (HiD) conference in Philadelphia (June 7).
Corcept Therapeutics Announces Presentations of Results of Pivotal Phase 3 GRACE Trial Evaluating Relacorilant in Patients with Hypercortisolism (Cushing's Syndrome)
MENLO PARK, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the results from GRACE, the Phase 3 trial of its proprietary selective cortisol modulator relacorilant in patients with hypercortisolism (Cushing's syndrome), will be presented at the Endocrine Society (ENDO) annual meeting in Boston (June 3) and the Heart in Diabetes (HiD) conference in Philadelphia (June 7).
05/31 12:35 EST - zacks.com
Corcept (CORT) Up 24.5% Since Last Earnings Report: Can It Continue?
Corcept (CORT) reported earnings 30 days ago. What's next for the stock?
Corcept (CORT) Up 24.5% Since Last Earnings Report: Can It Continue?
Corcept (CORT) reported earnings 30 days ago. What's next for the stock?
05/29 12:21 EST - zacks.com
Corcept (CORT) Rises as Cushing's Syndrome Study Meets Goal
Corcept's (CORT) phase III GRACE study, evaluating its lead candidate, relacorilant, for treating patients with Cushing's syndrome, meets the primary endpoint in a randomized withdrawal phase.
Corcept (CORT) Rises as Cushing's Syndrome Study Meets Goal
Corcept's (CORT) phase III GRACE study, evaluating its lead candidate, relacorilant, for treating patients with Cushing's syndrome, meets the primary endpoint in a randomized withdrawal phase.
05/07 12:15 EST - accesswire.com
Levi & Korsinsky, LLP Notifies Shareholders of Corcept Therapeutics Incorporated (CORT) an Upcoming Claims Deadline in a Class Action Settlement
NEW YORK, NY / ACCESSWIRE / May 7, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Corcept Therapeutics Incorporated (NASDAQ: CORT). The settlement provides for a fund of $14,000,000 to benefit class members.
Levi & Korsinsky, LLP Notifies Shareholders of Corcept Therapeutics Incorporated (CORT) an Upcoming Claims Deadline in a Class Action Settlement
NEW YORK, NY / ACCESSWIRE / May 7, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Corcept Therapeutics Incorporated (NASDAQ: CORT). The settlement provides for a fund of $14,000,000 to benefit class members.
05/02 12:46 EST - zacks.com
Corcept (CORT) Q1 Earnings & Revenues Surpass Estimates
Corcept (CORT) beats on both earnings and sales in the first quarter of 2024. The company increases revenue guidance for 2024.
Corcept (CORT) Q1 Earnings & Revenues Surpass Estimates
Corcept (CORT) beats on both earnings and sales in the first quarter of 2024. The company increases revenue guidance for 2024.
05/01 23:42 EST - seekingalpha.com
Corcept Therapeutics Incorporated (CORT) Q1 2024 Earnings Call Transcript
Corcept Therapeutics Incorporated (NASDAQ:CORT ) Q1 2024 Earnings Conference Call May 1, 2024 5:00 PM ET Company Participants Atabak Mokari - Chief Financial Officer Charlie Robb - Chief Business Officer Joe Belanoff - Chief Executive Officer William Guyer - Chief Development Officer Sean Maduck - President, Corcept Endocrinology Conference Call Participants Matt Kaplan - Ladenburg David Amsellem - Piper Sandler Swayampakula Ramakanth - H.C. Wainwright Operator Good day and thank you for standing by.
Corcept Therapeutics Incorporated (CORT) Q1 2024 Earnings Call Transcript
Corcept Therapeutics Incorporated (NASDAQ:CORT ) Q1 2024 Earnings Conference Call May 1, 2024 5:00 PM ET Company Participants Atabak Mokari - Chief Financial Officer Charlie Robb - Chief Business Officer Joe Belanoff - Chief Executive Officer William Guyer - Chief Development Officer Sean Maduck - President, Corcept Endocrinology Conference Call Participants Matt Kaplan - Ladenburg David Amsellem - Piper Sandler Swayampakula Ramakanth - H.C. Wainwright Operator Good day and thank you for standing by.
05/01 16:05 EST - globenewswire.com
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
MENLO PARK, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended March 31, 2024.
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
MENLO PARK, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended March 31, 2024.
04/24 16:05 EST - globenewswire.com
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
MENLO PARK, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update on May 1, 2024. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
MENLO PARK, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update on May 1, 2024. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
04/23 13:16 EST - zacks.com
Corcept (CORT) Posts Positive Data From Cushing's Syndrome Study
Corcept (CORT) reports positive data from the open-label portion of the phase III GRACE study evaluating relacorilant for treating patients with Cushing's syndrome.
Corcept (CORT) Posts Positive Data From Cushing's Syndrome Study
Corcept (CORT) reports positive data from the open-label portion of the phase III GRACE study evaluating relacorilant for treating patients with Cushing's syndrome.
04/17 13:01 EST - zacks.com
Corcept (CORT) Upgraded to Strong Buy: Here's What You Should Know
Corcept (CORT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Corcept (CORT) Upgraded to Strong Buy: Here's What You Should Know
Corcept (CORT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
04/17 08:30 EST - zacks.com
New Strong Buy Stocks for April 17th
BYRN, YMAB, SAND, CORT and ENVB have been added to the Zacks Rank #1 (Strong Buy) List on April 17, 2023.
New Strong Buy Stocks for April 17th
BYRN, YMAB, SAND, CORT and ENVB have been added to the Zacks Rank #1 (Strong Buy) List on April 17, 2023.
04/16 12:35 EST - zacks.com
Corcept (CORT) Completes Enrollment in Phase II ALS Study
The phase II DAZALS study is evaluating Corcept's (CORT) dazucorilant for treating patients with amyotrophic lateral sclerosis. Enrollment in the study is already complete.
Corcept (CORT) Completes Enrollment in Phase II ALS Study
The phase II DAZALS study is evaluating Corcept's (CORT) dazucorilant for treating patients with amyotrophic lateral sclerosis. Enrollment in the study is already complete.
04/09 12:11 EST - zacks.com
Corcept (CORT) Completes Enrollment in Ovarian Cancer Study
The phase III ROSELLA study is evaluating Corcept's (CORT) relacorilant plus nab-paclitaxel for treating recurrent, platinum-resistant ovarian cancer. Enrollment in the study has been completed.
Corcept (CORT) Completes Enrollment in Ovarian Cancer Study
The phase III ROSELLA study is evaluating Corcept's (CORT) relacorilant plus nab-paclitaxel for treating recurrent, platinum-resistant ovarian cancer. Enrollment in the study has been completed.
04/01 08:00 EST - globenewswire.com
Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing's Syndrome
MENLO PARK, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced completion of enrollment in GRADIENT, a Phase 3 trial of its proprietary selective cortisol modulator relacorilant in patients with Cushing's syndrome (hypercortisolism) caused by an adrenal adenoma or adrenal hyperplasia.
Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing's Syndrome
MENLO PARK, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced completion of enrollment in GRADIENT, a Phase 3 trial of its proprietary selective cortisol modulator relacorilant in patients with Cushing's syndrome (hypercortisolism) caused by an adrenal adenoma or adrenal hyperplasia.